Home > Insider Trading > Filing (0001189724-17-000003)

Filing Details

Accession Number:: 0001189724-17-000003
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-02-27 14:12:38
Reporting Period:: 2017-02-24

Filing Date:: 2017-02-27
Accepted Time:: 2017-02-27 14:12:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
883984	Icu Medical Inc	ICUI	Surgical & Medical Instruments & Apparatus (3841)	330022692

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1189724	Steven Riggs	951 Calle Amanecer San Clemente CA 92673	Vp Operations	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-02-24	16,250	$58.79	17,576	No	4	X	Direct
Common Stock	Disposition	2017-02-24	4,500	$151.39	13,076	No	4	S	Direct
Common Stock	Disposition	2017-02-24	11,750	$152.23	1,326	No	4	S	Direct
Common Stock	Acquisiton	2017-02-24	15,000	$58.79	16,326	No	4	X	Direct
Common Stock	Disposition	2017-02-24	4,796	$151.49	11,530	No	4	S	Direct
Common Stock	Disposition	2017-02-24	10,204	$152.20	1,326	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	X	Direct
No	4	S	Direct
No	4	S	Direct
No	4	X	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2017-02-24	16,250	$58.79	16,250	$58.79
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2017-02-24	15,000	$58.79	15,000	$58.79

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
46,250		2024-02-24	No	4	X	Direct
31,250		2024-02-24	No	4	X	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on August 11, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.95 to $151.90, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.95 to $152.85, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.95 to $151.90, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.95 to $152.80, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the grant date . Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of eh exercise price for 30 consecutive trading days.
Transaction is the exercise of a derivative security; see Column 2.